menu
    • menu
    [{"orgOrder":0,"company":"Xintong Pharmacy Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"Potassium\/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Xintong Pharmacy Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xintong Pharmacy Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xintong Pharmacy Company \/ Undisclosed"},{"orgOrder":0,"company":"The Young Investigator Group of Cardiovascular Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"Potassium\/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"The Young Investigator Group of Cardiovascular Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Young Investigator Group of Cardiovascular Research \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"The Young Investigator Group of Cardiovascular Research \/ Undisclosed"},{"orgOrder":0,"company":"Martin-Luther-Universit\u00e4t Halle-Wittenberg","sponsor":"Servier | KKS Netzwerk","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"Potassium\/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Martin-Luther-Universit\u00e4t Halle-Wittenberg","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Martin-Luther-Universit\u00e4t Halle-Wittenberg \/ Servier | KKS Netzwerk","highestDevelopmentStatusID":"8","companyTruncated":"Martin-Luther-Universit\u00e4t Halle-Wittenberg \/ Servier | KKS Netzwerk"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"Potassium\/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"University of California, San Diego \/ Amgen Inc"},{"orgOrder":0,"company":"Loyola University","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"Potassium\/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Loyola University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loyola University \/ Amgen Inc","highestDevelopmentStatusID":"11","companyTruncated":"Loyola University \/ Amgen Inc"},{"orgOrder":0,"company":"Duke University","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"Potassium\/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duke University \/ Amgen Inc","highestDevelopmentStatusID":"11","companyTruncated":"Duke University \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"Potassium\/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","graph1":"Undisclosed","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"Potassium\/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"Potassium\/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Amgen Inc"},{"orgOrder":0,"company":"Phillip Levy","sponsor":"Amgen Inc | iRhythm Technologies, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"Potassium\/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Phillip Levy","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Phillip Levy \/ Amgen Inc | iRhythm Technologies, Inc.","highestDevelopmentStatusID":"11","companyTruncated":"Phillip Levy \/ Amgen Inc | iRhythm Technologies, Inc."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"ZYUS Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ZYUS Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Ivabradine HCl

    Menu

    Ivabradine HCl

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alembic Pharmaceuticals Limited

                            India arrow
                            OTS 2025
                            Not Confirmed

                            Alembic Pharmaceuticals Limited

                            India arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alembic Pharma Gains USFDA Final Approval for Ivabradine Tablets, 5 mg and 7.5 mg

                            Details : Ivabradine, is a small molecule oral blocker of HCN channels, indicated to reduce the risk of hospitalisation for worsening heart failure in adults with stable, symptomatic chronic heart failure.

                            Product Name : Corlanor-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 12, 2024

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ZYUS Life Sciences

                            Canada arrow
                            OTS 2025
                            Not Confirmed

                            ZYUS Life Sciences

                            Canada arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zydus Lifesciences Gets USFDA Nod for Generic Heart Failure Treatment Drug

                            Details : USFDA approved generic version of Ivabradine, is a small molecule oral blocker of HCN channels, which is indicated to reduce the risk of hospitalisation for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with cer...

                            Product Name : Ivabradine-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 01, 2023

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            The Young Investigator Group of Cardiovascular Research

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            The Young Investigator Group of Cardiovascular Research

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support

                            Details : Ivabradine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 26, 2022

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Abbott Laboratories

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Abbott Laboratories

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Abbott’s Once-A-Day Ivabradine Receives DCGI Approval for Heart Failure and Angina patients

                            Details : Approval marks the first once-a-day formulation for Ivabradine in India, which will help increase adherence to therapy for chronic heart failure and chronic stable angina.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 02, 2020

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Amgen Inc

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipien...

                            Details : Ivabradine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 07, 2018

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Amgen Inc

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dys...

                            Details : Ivabradine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 07, 2018

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Loyola University

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Loyola University

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine

                            Details : Ivabradine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 02, 2018

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            University of California, San Diego

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            University of California, San Diego

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome

                            Details : Ivabradine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Postural Orthostatic Tachycardia Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 09, 2017

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Phillip Levy

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Phillip Levy

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Amgen Inc | iRhythm Technologies, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit

                            Details : Ivabradine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 30, 2017

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Amgen Inc | iRhythm Technologies, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.

                            Details : Ivabradine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 02, 2017

                            Lead Product(s) : Ivabradine Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth